safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

Articles

---

January 19th 2019

Double-Blinded Extension of the RADIANCE Trial Demonstrates the Efficacy and Safety of Ozanimod in Patients With Multiple Sclerosis

Cohen JA, Comi G, Arnold DL, et al RADIANCE Trial Investigators. Efficacy safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

Latest Updated Articles

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: October 7th 2024 | Updated: November 21st 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk